NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.90M
NBP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
NovaBridge BiosciencesNASDAQ: NBP
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation dips below year-ago levels
Q4 FY2025 stock-based compensation of $3.95M fell 65.2% year over year, behind the +1.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 62.0% from the prior quarter. Over 3 fiscal years it compounded at -74.4% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -65.2% toward the trailing-twelve-month pace of +1.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
Mixed currencies · from the cash flow
- Latest · FY2025
- 5.97M USD
- Year-over-year change
- —
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.97M | — |
| FY2024 | 2024-12-31 | (14.23M) | -238.6% |
| FY2023 | 2023-12-31 | 10.26M | -97.1% |
| FY2022 | 2022-12-31 | 357.15M | -41.3% |
| FY2021 | 2021-12-31 | 608.61M | — |
Stock-Based Compensation vs competitors
How NBP compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.1% is the 6th highest of 9, against a peer median of +7.9%.
- Over three fiscal years its annual growth of -74.4% compares with a peer median of +17.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.22M USD | -20.0% | +6.1% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥26.02M CNY | +1.1% | -74.4% | — |
| LTM Mar 2026 | $15.5M USD | -21.9% | -3.9% | — | |
| LTM Mar 2026 | $15.44M USD | +4.6% | +25.7% | 42886.1% | |
| LTM Mar 2026 | $14.93M USD | +11.2% | +10.0% | — | |
| LTM Mar 2026 | $14.63M USD | +18.7% | +30.7% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $12.14M USD | +60.2% | +336.5% | — |
| LTM Mar 2026 | $2.79M USD | +13.0% | +36.8% | — | |
| LTM Mar 2026 | $1.88M USD | -18.8% | -16.7% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $1.37M USD | — | — | — |
| LTM Dec 2025 | $0 USD | — | — | — | |
| Peer median (excluding NBP) | — | +7.9% | +17.8% | 42886.1% | |
Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (2.33B) | (2.51B) | (208.18M) | (362.72M) | (88.34M) |
| Depreciation & Amortization | 34.14M | 63.82M | 1.06M | 7.14M | 856K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 608.61M | 357.15M | 10.26M | (14.23M) | 5.97M |
| Change in Working Capital | 394.52M | 552.06M | (37.2M) | (20.52M) | 17.07M |
| Accounts Receivables | 97.42M | 33.08M | 0 | 0 | 0 |
| Inventory | (27.24M) | 27.24M | 0 | 0 | 0 |
| Accounts Payables | 107.85M | 0 | 0 | 0 | 0 |
| Other Working Capital | 216.49M | 491.75M | (37.2M) | (20.52M) | 17.07M |
| Other Non-Cash Items | 321.18M | 431.48M | 161.2M | 5.9M | 43.84M |
| Operating Cash Flow | (973.09M) | (1.1B) | (72.85M) | (384.42M) | (20.6M) |
| Capital Expenditures | (29.93M) | (45.83M) | (164.35K) | (350.34K) | (7K) |
| Acquisitions (Net) | (6M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (10.17B) | (7.41B) | 0 | (1.79B) | (49.96M) |
| Sales of Investments | 9.48B | 7.91B | 0 | 801.66M | 154.89M |
| Other Investing Activities | 0 | 26K | (107.47M) | 452.53K | 47K |
| Investing Cash Flow | (727.21M) | 458.38M | (107.63M) | (992.42M) | 104.97M |
| Debt Repayment | 0 | 2.75M | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 61.91M |
| Common Stock Repurchased | 0 | (3.08M) | (8.66M) | (2.45M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 593.92M | 60.86M | 407.88K | 0 | (4.19M) |
| Financing Cash Flow | 593.92M | 42.36M | (8.25M) | (2.44M) | 57.73M |
| Effect of Forex Changes | (128.77M) | 389.2M | 36.89M | (327.04M) | 276K |
| Net Change in Cash | (1.24B) | (212.86M) | (151.58M) | (1.71B) | 142.37M |
| Free Cash Flow | (1B) | (1.15B) | (73.02M) | (384.77M) | (20.6M) |
NovaBridge Biosciences
NASDAQ:NBP
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.